Family Med Medical News

Your Unread Messages

See All

Hello, Mary O'connor
Manage E-mail | Logout

Most Viewed Abstracts

1. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

2. Omega-3 fatty acids for bipolar disorder

3. Is folic acid good for everyone

4. ACS Releases Guidelines for HPV Vaccination

5. Vitamin D - A review Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients
Journal of Rheumatology, 11/10/09

Favia G et al. – ONJ is a harmful side effect of bisphosphonate therapies. Clinicians must be aware of this entity, inform patients of the risks related to dental surgery, and possibly undertake adequate preventive measures.

Methods

Over 4 year period, total of 102 bisphosphonate-treated patients affected by ONJ identified
24 patients underwent bisphosphonate therapy for non-neoplastic disease and profile analyzed

Results

In study cohort, bisphosphonates administered mainly for postmenopausal osteoporosis (20/24 patients, 83.3%)
Duration of therapy until presentation of ONJ ranging from 11 to 40 months
Most common triggering event dentoalveolar surgery
All patients nonsmokers
6 manifested multiple ONJ lesions
3 had possible comorbidities
Surgical debridement performed in 19 patients for total of 22 lesions, which were individually considered in followup
Latter showed complete remission of ONJ in 21/22 lesions

<< Previous
Despite evidence-based guidelines, systolic blood pressure...

Next >>
Hand syndromes associated with diabetes: Impairments and obesity...